Enliven Therapeutics ELVN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$103.69M-16.5% | -$89.02M-24.4% | -$71.58M-90.1% | -$37.66M+26.7% | ||
| $263K-17.0% | $317K+6.7% | $297K+38.1% | $215K+117% | ||
| $34.02M+68.6% | $20.17M+56.2% | $12.91M+305% | $3.19M-17.0% | ||
| -$70.3M+3.9% | -$73.19M-19.5% | -$61.27M-91.0% | -$32.08M+31.4% | ||
| —— | $44K-70.5% | $149K-75.7% | $612K— | ||
| -$186.22M— | —— | —— | -$612K+62.5% | ||
| $219.24M+64.6% | $133.17M— | —— | -$1.8M-104% | ||
| —— | $23.98M— | —— | -$34.49M— | ||
| -$70.46M+3.8% | -$73.24M-19.2% | -$61.42M-87.9% | -$32.69M+30.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Enliven Therapeutics generate?
- Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
- What is Enliven Therapeutics's free cash flow?
- After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
- Where does Enliven Therapeutics's cash flow data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.